Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators.

N Engl J Med. 2004 Nov 11;351(20):2049-57. Epub 2004 Nov 8. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276.

2.

Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.

Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators.

Circulation. 2007 Apr 3;115(13):1747-53. Epub 2007 Mar 19.

3.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al.

N Engl J Med. 1991 Aug 1;325(5):303-10.

4.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators.

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
6.

The African American Heart Failure Trial: a clinical trial update.

Taylor AL.

Am J Cardiol. 2005 Oct 10;96(7B):44-8. Epub 2005 Aug 9. Review.

PMID:
16226935
7.

Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.

Taylor AL, Sabolinski ML, Tam SW, Ziesche S, Ghali JK, Archambault WT, Worcel M, Cohn JN; A-HeFT Investigators.

J Card Fail. 2012 Aug;18(8):600-6. doi: 10.1016/j.cardfail.2012.06.526.

PMID:
22858074
8.

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, et al.

N Engl J Med. 1986 Jun 12;314(24):1547-52.

9.

Isosorbide dinitrate and hydralazine in blacks with heart failure.

Eisenberger AB.

N Engl J Med. 2005 Mar 10;352(10):1041-3; author reply 1041-3. No abstract available.

PMID:
15761995
11.

Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.

Hammermeister KE, Fairclough D, Emsermann CB, Hamman R, Ho M, Phibbs S, Plomondon M, Valuck R, West D, Steiner JF.

Clin Ther. 2009 Mar;31(3):632-43. doi: 10.1016/j.clinthera.2009.03.019.

PMID:
19393854
13.

Isosorbide dinitrate and hydralazine in blacks with heart failure.

Chow AY.

N Engl J Med. 2005 Mar 10;352(10):1041-3; author reply 1041-3. No abstract available.

PMID:
15761997
14.
15.

Color blind, or just plain blind?

Czap A.

Altern Med Rev. 2005 Jun;10(2):81-2. No abstract available.

16.

G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.

McNamara DM, Taylor AL, Tam SW, Worcel M, Yancy CW, Hanley-Yanez K, Cohn JN, Feldman AM.

JACC Heart Fail. 2014 Dec;2(6):551-7. doi: 10.1016/j.jchf.2014.04.016. Epub 2014 Oct 8.

PMID:
25306451
17.

Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.

Thadani U, Jacob RG.

Drugs Today (Barc). 2008 Dec;44(12):925-37. doi: 10.1358/dot.2008.44.12.1131826.

PMID:
19198701
18.
19.

Isosorbide dinitrate and hydralazine in blacks with heart failure.

Bellin EY.

N Engl J Med. 2005 Mar 10;352(10):1041-3; author reply 1041-3. No abstract available.

PMID:
15761996
20.

Supplemental Content

Support Center